These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 9468582

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma.
    Yamada M, Yanaba K, Takehara K, Sato S.
    Arch Dermatol Res; 2005 Dec; 297(6):256-60. PubMed ID: 16222535
    [Abstract] [Full Text] [Related]

  • 3. The serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble gp130 (sgp130) in different tumour stages. Correlation between the two parameters in progression of malignancy.
    Kovacs E.
    Biomed Pharmacother; 2005 Oct; 59(9):498-500. PubMed ID: 16202558
    [Abstract] [Full Text] [Related]

  • 4. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
    López-Lerma I, Estrach MT.
    J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
    [Abstract] [Full Text] [Related]

  • 5. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
    Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL.
    Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
    [Abstract] [Full Text] [Related]

  • 6. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R.
    Cancer Res; 1997 Aug 01; 57(15):3149-53. PubMed ID: 9242442
    [Abstract] [Full Text] [Related]

  • 7. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
    Liakopoulos V, Eleftheriadis T, Kyropoulos T, Voliotis G, Potamianos S, Zengos N, Stefanidis I, Heintz B.
    Ren Fail; 2005 Aug 01; 27(3):315-21. PubMed ID: 15957549
    [Abstract] [Full Text] [Related]

  • 8. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients.
    Toiyama Y, Miki C, Inoue Y, Okugawa Y, Koike Y, Yokoe T, Tanaka K, Kusunoki M.
    Ann Surg Oncol; 2008 Jun 01; 15(6):1617-24. PubMed ID: 18368454
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of serum VEGF in melanoma patients: a pilot study.
    Ascierto PA, Leonardi E, Ottaiano A, Napolitano M, Scala S, Castello G.
    Anticancer Res; 2004 Jun 01; 24(6):4255-8. PubMed ID: 15736481
    [Abstract] [Full Text] [Related]

  • 10. The prognostic significance of serum levels of soluble intercellular adhesion molecules-1 in patients with primary extranodal non-Hodgkin lymphomas.
    Lei KI, Johnson PJ.
    Cancer; 2000 Sep 15; 89(6):1387-95. PubMed ID: 11002235
    [Abstract] [Full Text] [Related]

  • 11. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with colorectal cancer.
    Basoglu M, Yildirgan MI, Taysi S, Yilmaz I, Kiziltunc A, Balik AA, Celebi F, Atamanalp SS.
    J Surg Oncol; 2003 Jul 15; 83(3):180-4. PubMed ID: 12827689
    [Abstract] [Full Text] [Related]

  • 12. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
    Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP, Meunier L.
    Br J Dermatol; 2005 May 15; 152(5):948-53. PubMed ID: 15888151
    [Abstract] [Full Text] [Related]

  • 13. Correlation between soluble intercellular adhesion molecule 1 level and extracellular superoxide dismutase activity in rheumatoid arthritis: a possible association with disease activity.
    Ugur M, Yildirim K, Kiziltunc A, Erdal A, Karatay S, Senel K.
    Scand J Rheumatol; 2004 May 15; 33(4):239-43. PubMed ID: 15370719
    [Abstract] [Full Text] [Related]

  • 14. Results of the determination of serum markers in patients with malignant melanoma.
    Lugović L, Situm M, Buljan M, Poduje S, Sebetić K.
    Coll Antropol; 2007 Jan 15; 31 Suppl 1():7-11. PubMed ID: 17469741
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
    Ye Z, Kageshita T, Ishihara T, Ito S, Ono T.
    J Dermatol; 1995 May 15; 22(5):370-5. PubMed ID: 7673560
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK, Lederer M, Kaufmann M, Hein R, Stolz W, Apfel R, Bogdahn U, Buettner R.
    Anticancer Res; 1999 May 15; 19(4A):2691-3. PubMed ID: 10470221
    [Abstract] [Full Text] [Related]

  • 20. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
    Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, Laurent R, Humbert P, Aubin F.
    Br J Dermatol; 2005 Apr 15; 152(4):685-9. PubMed ID: 15840099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.